Skip to content
Screener

Design Therapeutics, Inc. DSGN Q3 2025 earnings

Reported November 5, 2025 · Before market open

Revenue-
EPS-$0.30Beat by $0.04
EPS estimate-$0.34

Next report

Nov 4, 2026 (in 2 months)
EPS estimate-$0.38

Financials

Q3 2025

Income statement

See full
Revenue-—
Operating income-$19.3M-18.9%
Net income-$17.0M-30.4%
EPS (diluted)-$0.30-30.4%

Balance sheet

See full
Cash & equivalents$15.1M-50.3%
Total debt$1.7M-30.9%
Total equity$199.7M-20.9%
Total assets$211.8M-19.1%

Cash flow

See full
Operating cash flow-$11.2M-16.9%
CapEx-—
Free cash flow-$11.2M-17.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$428.82M+40.9%
Enterprise value$415.47M+50.3%

Returns & leverage

See full
Return on equity-29.8%+62.7pp
Debt / equity0×0.0×
Current ratio18.7×-15.9×

FAQ

When did Design Therapeutics, Inc. report Q3 2025 earnings?
Design Therapeutics, Inc. (DSGN) reported Q3 2025 earnings on November 5, 2025 before market open.
What were Design Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Design Therapeutics, Inc. reported revenue of - and eps of $-0.30 for Q3 2025.
Did Design Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.34 by $0.04.
How did Design Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 30.4% from $-0.23.
Where can I find Design Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-266933) and the 10-Q periodic report (0001193125-25-266970) directly on SEC EDGAR. The filing index links above go to sec.gov.